<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076838</url>
  </required_header>
  <id_info>
    <org_study_id>DIAZ.001.08</org_study_id>
    <nct_id>NCT05076838</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy</brief_title>
  <official_title>An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO® With Open-Label Safety Period in Pediatric Subjects With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurelis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurelis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2a, open-label, single-dose, PK study of VALTOCO with open-label safety&#xD;
      period in pediatric epilepsy subjects age 2 to 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of diazepam after intranasal VALTOCO administered to subjects with epilepsy 2 to 5 years of age</measure>
    <time_frame>0-6 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Valtoco In Pediatric Subjects with Epilepsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam Nasal Spray [Valtoco]</intervention_name>
    <description>5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.</description>
    <arm_group_label>Valtoco In Pediatric Subjects with Epilepsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a clinical diagnosis of epilepsy and, in the opinion of the Investigator,&#xD;
             may need benzodiazepine intervention for seizure control.&#xD;
&#xD;
          -  Subjects having either partial or generalized epilepsy with motor seizures or seizures&#xD;
             with clear alteration of awareness, for which rescue medications are used&#xD;
             approximately once per month for the last 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects whose body weight are &lt; 6 kg or &gt; 33 kg.&#xD;
&#xD;
          -  Subject is undergoing intracranial electroencephalogram (EEG) monitoring.&#xD;
&#xD;
          -  A history of clinically significant gastrointestinal, renal, hepatic, neurologic,&#xD;
             hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or&#xD;
             cardiovascular disease, severe seasonal or non-seasonal allergies, nasal polyps or any&#xD;
             nasal passage abnormality.&#xD;
&#xD;
          -  Subject has had significant traumatic injury, major surgery or open biopsy within 30&#xD;
             days prior to study screening.&#xD;
&#xD;
          -  Participation in a clinical trial within 30 days prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Inadequate or difficult venous access that may jeopardize the quality or timing of the&#xD;
             PK samples.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cyndi Guerra</last_name>
    <phone>(973) 615-6258</phone>
    <email>cguerra@neurelis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwest Florida Clinical Research Group, LLC.</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genei Bougher, APRN</last_name>
    </contact>
    <investigator>
      <last_name>Ben Renfroe, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Rare Neurological Diseases</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Tarquinio, D.O.</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Tarquinio, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Regional Epilepsy Group</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Butryn</last_name>
    </contact>
    <investigator>
      <last_name>Eric Segal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Strunc, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Michael Strunc, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

